The PD-1 immunotherapy approach is a therapeutic modality for antitumor therapy by inhibiting the binding of PD-1 and PD-L1 to release immunosuppression. T cells (a type of white blood cell) express PD-1 (programmed death receptor-1) on their surface, and many tumor cells express PD-L1, a ligand of PD-1, on their surface. Tumor cells proliferate abnormally through the binding of PD-L1 to the PD-1 of the T cells to inhibit the immune action of the T cells and to achieve the immune escape of the tumor cells. PD-1 immunotherapy is to block the PD-1/PD-L1 pathway with PD-1 inhibitors to activate the immune function of T cells and achieve anti-tumor effect, which can be used for the treatment of non-small-cell lung cancer, melanoma, uroepithelial carcinoma, and Hodgkin’s lymphoma. PD-1 inhibitors include pembrolizumab, atezolizumab, derucizumab, etc. It is recommended that patients with indications for PD-1 immunotherapy should take into account their own physical and economic conditions, and some of the patients can obtain good therapeutic effects with this treatment.